Radioimmunotherapy of mice bearing breast tumors with 177Lu-labeled trastuzumab

被引：12
|
作者：
Rasaneh, Samira [2 ]
Rajabi, Hossein [1 ]
Akhlaghpoor, Shahram [3 ]
Sheybani, Shahab [2 ]
机构：
[1] Tarbiat Modares Univ, Dept Med Phys, Tehran, Iran
[2] Nucl Sci & Technol Res Inst, Tehran, Iran
[3] Tehran Med Univ, Sina Hosp, Noor Med Imaging Ctr, Tehran, Iran
来源：
TURKISH JOURNAL OF MEDICAL SCIENCES | 2012年 / 42卷
关键词：
Radioimmunotherapy; breast cancer; lutetium-177; trastuzumab; gamma camera imaging; CELL LUNG-CANCER; NUDE-MICE; MONOCLONAL-ANTIBODIES; ABSORBED FRACTIONS; BIODISTRIBUTION; MODEL; LU-177; HER-2/NEU; ONCOGENE; AGENT;
D O I：
10.3906/sag-1105-29
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Aim: In the present study, we investigated the therapeutic efficacy of trastuzumab labeled with lutetium-177 (Lu-177) in mice bearing breast tumors. Materials and methods: Trastuzumab was labeled with 177Lu via DOTA as a chelator. In vitro and in vivo quality control tests of incorporated activity, immunoreactivity, stability of Lu-177 trastuzumab, biodistribution, and imaging studies were performed. Therapeutic efficacy and dosimetry studies were carried out in mice with breast tumors. Results: The good in vitro and in vivo quality control results suggested that (177)Tu trastuzumab could be used as a radioimmunotherapy agent. Reductions of 81% and 98% in the mean tumor volume for the group that received Lu-177-trastuzumab [7.4 MN] were observed at 42 and 45 days after treatment, respectively. Conclusion: The results showed that Lu-177-trastuzumab could be considered as a possible new radiopharmaceutical agent for use in radioimmunotherapy of breast cancer in humans.
引用
收藏
页码：1292 / 1298
页数：7
相关论文
共 50 条
  • [1] Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody
    Ehlerding, Emily B.
    Lacognata, Saige
    Jiang, Dawei
    Ferreira, Carolina A.
    Goel, Shreya
    Hernandez, Reinier
    Jeffery, Justin J.
    Theuer, Charles P.
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (01) : 123 - 131
  • [2] Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody
    Emily B. Ehlerding
    Saige Lacognata
    Dawei Jiang
    Carolina A. Ferreira
    Shreya Goel
    Reinier Hernandez
    Justin J. Jeffery
    Charles P. Theuer
    Weibo Cai
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 123 - 131
  • [3] The Synthesis, Radiolabeling, and Characterization of 177Lu-Labeled Tetrazine Radioligands for Pretargeted Radioimmunotherapy
    Membreno, Rosemery
    Houghton, Jacob
    Cook, Brendon
    Carnazza, Kathryn
    Lewis, Jason
    Zeglis, Brian
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [4] Targeting Breast Cancer Using 177Lu-Labeled Trastuzumab and Trastuzumab Fragment First-in-Human Clinical Experience
    Rathore, Yogesh
    Lakhanpal, Tamanna
    Chakraborty, Sudipta
    Chakravarty, Rubel
    Mittal, B. R.
    Irrinki, R. N. Santhosh
    Laroiya, Ishita
    Kaur, Komalpreet
    Shukla, Jaya
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : e258 - e265
  • [5] Radioimmunotherapy of prostate cancer with a bispecific antibody and a 177Lu-labeled peptide in a nude mouse model
    van Rij, C. M.
    Frielink, C.
    Sharkey, R. M.
    McBride, W. J.
    Rossi, E. A.
    Chang, C. -H.
    Oyen, W. J.
    Goldenberg, D. M.
    Boerman, O. C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S157 - S157
  • [6] Radioimmunotherapy of Mice with HER-2 Positive SKOV-3 Xenografts Using 227Th- and 177Lu-labeled p-benzyl-DOTA-trastuzumab.
    Abbas, N.
    Bruland, O.
    Borrebaek, J.
    Larsen, A.
    Brevik, E.
    Dahle, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S314 - S314
  • [7] Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
    Abbas, Nasir
    Bruland, Oyvind Sverre
    Brevik, Ellen Mengshoel
    Dahle, Jostein
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (08) : 838 - 847
  • [8] Does 177Lu-labeled octreotate improve the rate of remission of endocrine gastroenteropancreatic tumors?
    Eberle A.N.
    Beglinger C.
    Nature Clinical Practice Endocrinology & Metabolism, 2005, 1 (1): : 20 - 21
  • [9] Click-cleavable 111In/177Lu-labeled DOTA-TCO-trastuzumab for imaging and therapy of breast cancer
    de Roode, Kim
    Versteegen, Ron
    Kleijn, Laurens
    Rossin, Raffaella
    Robillard, Marc
    NUCLEAR MEDICINE AND BIOLOGY, 2022, 114 : S16 - S16
  • [10] Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
    Oscar Ardenfors
    Joachim N. Nilsson
    Daniel Thor
    Cecilia Hindorf
    EJNMMI Physics, 9
12345